Clinical trials: Neurocognitive Disorder
Alzheimer Disease
Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment (MCI)
In the ADDITION-MCI project, patients with a diagnosis of mild cognitive impairment probably caused by Alzheimer's disease will receive plasma exchange.
- Trial name
- ADDITION-MCI (NCT06234436)
- Testing
- Plasma exchenge
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Oslo University Hospital
IDA - Iron Deficiency Anemia, Anemia
Iron Deficiency Anemia (IDA) and the Brain
This is a trial with an observational and an interventional arm, in patients with moderate to severe anemia and control subjects.
- Conditions
- IDA - Iron Deficiency Anemia, Anemia, Iron Deficiency Anemia, Anemia, Iron Deficiency
- Trial name
- IDA (NCT05929729)
- Testing
- Ferric derisomaltose, NovaFerrum
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Los Angeles
Alzheimer Disease
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo.
- Trial name
- NCT03446001
- Testing
- TRx0237 16 mg/day, Control, TRx0237 8 mg/day
- Where
- 103 sites in United States, Belgium and 6 more
- Volunteers
- 598 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm…
- Trial name
- NCT07762092
- Testing
- No Intervention
- Where
- 17 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Cognition Disorder
Cognitive and Speech Disorders in Children With Congenital Heart Defects
The study is aimed to found out expressive speech disorders as a sign of neurocognitive development delay in children with congenital heart defects before and after surgery
- Trial name
- NCT06565299
- Testing
- Cardiovascular surgery with cardiopulmonary bypass
- Where
- Russia
- Volunteers
- 217 people
- Sponsor
- Kemerovo State Medical University
Pediatric Retinoblastoma, Retinoblastoma
Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
The purpose of this study is to see if there is a difference between the development of the brain (neurodevelopment) in children who have been treated for retinoblastoma with multiple anesthetic exposures, compared with brain…
- Trial name
- NCT03546387
- Testing
- Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V), California Verbal Learning Test, Children's Version, Beery Developmental Test of Visual Motor Integration, 6th edition
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epilepsy, Cognitive Dysfunction, Cognitive Disorder
HOBSCOTCH-YOUTH and Young Adults
The goal of this clinical trial is to learn more about the home-based epilepsy self-management program, HOBSCOTCH, for improving cognitive function (thinking and memory) and quality of life specifically in young adults, ages 18 …
- Conditions
- Epilepsy, Cognitive Dysfunction, Cognitive Disorder, Memory and Thinking Problems
- Trial name
- NCT07735715
- Testing
- HOBSCOTCH/HOBSCOTCH-YOUTH
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Neurocognitive Dysfunction
Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI
The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation.
- Trial name
- MEMENTO (NCT06275035)
- Testing
- Memantine Oral Tablet
- Where
- India
- Volunteers
- 101 people
- Sponsor
- Tata Memorial Centre
Dementia
Safety and Efficacy of Electroconvulsive Therapy (ECT) for Behavioural and Psychological Symptoms of Dementia (BPSD)
This is a prospective, open-label, observational study of the efficacy and safety of ECT for BPSD. There is no control or comparison group.
- Trial name
- ECTBPSD (NCT02969499)
- Where
- 3 sites in Canada
- Volunteers
- 33 people
- Sponsor
- University of British Columbia
Alzheimer Disease
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
- Trial name
- NCT02248116
- Testing
- Talsaclidine
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Dementia, Diagnostic Tests, Routine
SIB-Norwegian Version, Validation and Reliability Study
The purpose of this study is to validate and to test interrater reliability for the Norwgian version of Severe Impairment Battery (SIB).
- Trial name
- NCT00449384
- Testing
- Diagnostic Screening
- Where
- Norway
- Volunteers
- 59 people
- Sponsor
- Sykehuset Innlandet HF
Delirium on Emergence
Post Anesthesia Emergence and Behavioral Changes in Children Undergoing MRI
Children who receive general anesthesia may become agitated (emergence delirium) in the recovery period. This occurs more often after inhalational anesthetics, particularly sevoflurane and desflurane than after propofol.
- Trial name
- NCT02111447
- Testing
- Propofol, Sevoflurane, Isoflurane
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- State University of New York at Buffalo
Dementia
Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD
The aim of this study is to discontinue antipsychotics and antidepressants, and to study its effect on Behavioural- and Psychological Symptoms in Dementia (BPSD).
- Trial name
- NCT00433121
- Testing
- Risperidone, Olanzapine, Haloperidole
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Sykehuset Innlandet HF
Alzheimer's Disease
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102.
- Trial name
- NCT00606476
- Testing
- Bapineuzumab (AAB-001)
- Where
- 29 sites in United States
- Volunteers
- 194 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer Disease, Periodontitis
Periodonitis and Alzheimer's Disease
The main objective of this study is to assess whether Periodontal Disease is more prevalent in adult patients diagnosed with Alzheimer's Disease compared to adult patients without Alzheimer's Disease.
- Trial name
- NCT05189132
- Testing
- Periodontal Diagnosis, Microbiological analysis, Inflammatory mediators
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Lisbon
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Cognitive Disorder, Metabolic Disease
Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency
Background: Creatine transporter deficiency (CTD) is a genetic disorder that mainly affects the brain in males. CTD causes intellectual disability that can be mild to severe.
- Conditions
- Cognitive Disorder, Metabolic Disease, Autism Spectrum Disorder
- Trial name
- NCT05600946
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Down Syndrome, Cognitive Dysfunction
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10
The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of cognitive dysfunction shown by children with Down syndrome, aged 6 to 10 years.
- Trial name
- NCT00754013
- Testing
- Aricept (Donepezil hydrochloride)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease (AD), Time Perception
Evaluation of a Neuropsychological Tool to Assess Temporal Processing Abilities in Alzheimer's Disease
Perceiving and representing the passage of time allows us to temporally organize perceptions and memories for the coordination of actions, planning, and the mobilization of cognitive processes toward a goal.
- Trial name
- CHRONOS (NCT07341009)
- Testing
- Chronos battery
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.